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Abstract 
The cardiac fibroblast (CF) is a multifunctional and heterogeneous cell type that plays an 
essential role in regulating cardiac development, structure and function. Following 
myocardial infarction (MI), the myocardium undergoes complex structural remodelling in an 
attempt to repair the damaged tissue and overcome the loss of function induced by 
ischemia/reperfusion injury. Evidence is emerging that CF play critical roles in all stages of 
post-MI remodelling, including the initial inflammatory phase that is triggered in response to 
myocardial damage. CF are particularly responsive to the proinflammatory cytokine 
interleukin-1 (IL-1) whose levels are rapidly induced in the myocardium after MI. Studies 
from our laboratory in recent years have sought to evaluate the functional effects of IL-1 on 
human CF function and to determine the underlying molecular mechanisms. This review 
summarises these data and sets it in the context of post-MI cardiac remodelling, identifying 
the fibroblast as a potential therapeutic target for reducing adverse cardiac remodelling and 
its devastating consequences.   
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1. Introduction 
Cardiac fibroblasts (CF) are the major cellular components of the heart, outnumbering 
cardiomyocytes by as many as 2:1 (Jugdutt, 2003; Banerjee et al., 2007). These 
multifunctional and heterogeneous cells play important roles in many aspects of cardiac 
structure and function including its embryonic development, normal physiology and 
pathophysiology (Brown et al., 2005; Camelliti et al., 2006; Porter and Turner, 2009; 
Krenning et al., 2010; van den Borne et al., 2010; Turner and Porter, 2013). CF are 
particularly important regulators of the myocardial extracellular matrix (ECM). As well as 
controlling synthesis of structural ECM components (e.g. collagens, laminins, fibronectin), 
CF are also a source of ECM-regulatory molecules including matricellular proteins (e.g. 
thrombospondins, CCNs, tenascins), matrix metalloproteinases (MMPs) and MMP inhibitors 
(TIMPs). The close proximity of fibroblasts to cardiomyocytes and other myocardial cell 
types facilitates inter-cellular communication via both physical interactions (e.g. gap 
junctions) and via local paracrine signalling networks (e.g. synthesis and secretion of growth 
factors and cytokines), and hence CF are able to influence multiple aspects of cardiac 
function. 
 CF are intrinsically involved in the complex structural remodelling of the heart that 
occurs following myocardial infarction (MI), as well as in other cardiac pathologies that can 
lead to heart failure including hypertension, cardiomyopathy and myocarditis (Brown et al., 
2005; Porter and Turner, 2009; Krenning et al., 2010; van den Borne et al., 2010; Turner and 
Porter, 2013). Aspects of CF function that are particularly pertinent to myocardial 
remodelling include their ability to proliferate, migrate in response to chemotactic stimuli, 
differentiate into myofibroblasts, regulate ECM turnover and synthesise and secrete 
numerous autocrine/paracrine signalling molecules, including growth factors, angiogenic 
factors and inflammatory cytokines and chemokines (Porter and Turner, 2009).  
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 Following MI, the myocardium undergoes complex structural remodelling in an 
attempt to repair the damaged tissue and to overcome the loss of function induced by 
ischemia/reperfusion injury (Jugdutt, 2003). Post-MI remodelling occurs through a highly 
organised series of events involving both resident myocardial cells and infiltrating extra-
cardiac cells such as neutrophils, monocyte/macrophages and myofibroblast precursors. The 
post-MI healing process can be divided into three overlapping stages referred to as the 
inflammatory, granulation (proliferative) and maturation phases (Frangogiannis, 2008; van 
Nieuwenhoven and Turner, 2013). It is becoming increasingly apparent that CF are critically 
involved in all these stages of myocardial repair and remodelling. 
 
2. Cardiac Fibroblasts and Post-MI Remodelling 
2.1. Inflammatory phase 
Recent evidence suggests that CF can act as early triggers of the myocardial inflammatory 
response, preceding the infiltration of inflammatory cells (Kawaguchi et al., 2011). Although 
cardiomyocytes undergo rapid necrotic cell death in response to ischaemia, CF appear to be 
less sensitive to oxygen and nutrient starvation (Zhang et al., 2001) and could therefore be 
important sensors of early cardiomyocyte damage. The close positioning of myocytes and 
fibroblasts in the heart, coupled with recent evidence that CF express components of the 
innate immune system including Toll-like receptors and NOD-like receptors (Strand et al., 
2013; Fernandez-Velasco et al., 2012), suggests that fibroblasts are able to rapidly sense 
endogenous danger signals known as damage-associated molecular patterns (DAMPs) that 
occur following myocyte damage and necrosis (Arslan et al., 2011; Zheng et al., 2011). 
Importantly, CF express a functional inflammasome that facilitates activation and secretion of 
the proinflammatory cytokine IL-1β (Kawaguchi et al., 2011); one of the main triggers for the 
myocardial inflammatory response. In addition to IL-1β, CF are capable of secreting a host of 
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other proinflammatory cytokines and chemokines including tumor necrosis factor (TNF), 
IL-6, IL-33, CC chemokines (e.g. CCL2/MCP-1) and CXC chemokines (e.g. 
CXCL1/GRO/KC and CXCL8/IL-8,) in a feed-forward loop driven by the inflammatory 
milieu, thereby exacerbating the initial inflammatory response (Turner et al., 2007; Turner et 
al., 2009; Turner et al., 2011; Demyanets et al., 2013; LaFramboise et al., 2007). Although 
further studies are required to determine the precise relative contribution of CF in this early 
inflammatory stage of remodelling compared with other cell types (mast cells, neutrophils, 
monocyte/macrophages etc), the available evidence to date suggests that CF play an 
important role (Chen and Frangogiannis, 2012). 
 
2.2. Granulation phase 
CF are also integrally involved in the granulation phase of remodelling, the transitional stage 
between inflammation and fibrosis (Chen and Frangogiannis, 2012; van Nieuwenhoven and 
Turner, 2013). Granulation tissue comprises mostly macrophages and myofibroblasts, the 
latter being derived from a variety of sources including resident CF, endothelial cells, 
epithelial cells, bone marrow-derived fibrocytes, pericytes and smooth muscle cells 
(Krenning et al., 2010; Zeisberg and Kalluri, 2010). Myofibroblasts are a differentiated form 
of fibroblasts, characterised by increased alpha-smooth muscle actin (SMA) expression, that 
are not present in the normal healthy myocardium (Tomasek et al., 2002; van den Borne et 
al., 2010). In response to proinflammatory stimuli such as IL-1 and TNF, myofibroblasts 
produce high levels of ECM-degrading proteases (especially MMPs) to degrade the damaged 
tissue prior to clearance by phagocytic leukocytes. This ECM degradation also facilitates 
(myo)fibroblast migration into the infarct area where they undergo increased proliferation in 
response to mitogenic stimuli, thus rapidly increasing local myofibroblast numbers. 
Neovascularisation is an important component of the granulation phase, and (myo)fibroblasts 
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likely contribute to this through their ability to modulate endothelial cell function, for 
example through secretion of VEGF (Zhao and Eghbali-Webb, 2001). In addition to their 
effects on MMPs, proinflammatory cytokines such as IL-1 may also be important stimulators 
of VEGF secretion and activity at the level of the fibroblast (Turner et al., 2010). 
 
2.3. Maturation phase 
As the granulation phase progresses, increased levels of pro-fibrotic molecules (e.g. TGFβ, 
CTGF/CCN2), combined with a reduction in inflammatory signals (e.g. IL-1), drive a switch 
in myofibroblast function away from ECM degradation towards synthesis of structural ECM 
components (particularly collagen I and III) and scar formation (Chen and Frangogiannis, 
2012; van Nieuwenhoven and Turner, 2013). Myofibroblasts are the most prevalent cell type 
in scar tissue and are the main effectors of fibrogenesis (Peterson et al., 1999). Their 
expression of contractile cytoskeletal proteins (e.g. SMA) and focal adhesion proteins (e.g. 
paxillin, integrin Vβ3) enables mechanical contraction of the scar edges to facilitate wound 
healing and scar maturation (Tomasek et al., 2002).  
 
2.4. Reactive fibrosis 
Although myofibroblast numbers decrease rapidly after scar formation, they can persist in the 
healed scar for many years after MI (Willems et al., 1994) and may be important for 
maintaining the strength and flexibility of the scar (van den Borne et al., 2010; Turner and 
Porter, 2013). However, persistent myofibroblast activation and continual local production of 
inflammatory cytokines, particularly in non-damaged areas of the myocardium (reactive 
fibrosis), can promote sustained inflammation, neurohormonal activation, ventricular wall 
stiffening, cardiac dysfunction and eventually heart failure (Brown et al., 2005).               
 
7 
 
3. Interleukin-1 and Post-MI Remodelling 
3.1. IL-1 in the heart 
The proinflammatory cytokine IL-1 comprises two distinct gene products (IL-1 and IL-1β) 
that have indistinguishable biological activities mediated via activation of the cell surface 
receptor IL-1R1 (Dinarello, 2011; Arend et al., 2008). A third receptor ligand, IL-1RA (IL-1 
receptor antagonist), is structurally related to IL-1 and IL-1β but acts as an inhibitor of IL-1 
signalling as it binds to, but does not activate, the IL-1R1 receptor complex. Increased 
myocardial IL-1/β levels are associated with many cardiovascular pathologies including MI, 
cardiomyopathy, hypertension and myocarditis (Long, 2001; Bujak and Frangogiannis, 
2009). As neither IL-1 nor IL-1β molecules possess leader sequences they are unable to be 
secreted from cells via the normal Golgi-mediated vesicular transport pathway. 
 IL-1 is an intracellular cytokine localised to the cytosol and also the nucleus where it 
appears to activate transcription of inflammatory genes (Werman et al., 2004). IL-1 is only 
released from cells when they are damaged or undergo necrotic cell death, and is one of the 
DAMPs that trigger the innate immune response. A similar role has been ascribed to other IL-
1 family members such as IL-33 (Demyanets et al., 2013). IL-1 is a key trigger for sterile 
inflammation in the liver (Chen et al., 2007), and it likely plays a similar role in the heart 
following myocyte necrosis given that cardiac myocytes (Westphal et al., 2007) and 
fibroblasts (Turner et al., 2007) express IL-1, and IL-1 levels are increased in the infarcted 
myocardium (Timmers et al., 2008).  
 In contrast to IL-1, IL-1β is actively secreted from cells via non-classical pathways 
in response to specific stimuli (Arend et al., 2008) and is one of the earliest cytokines 
detected in patient plasma following MI (Guillen et al., 1995). Innate immune responses 
triggered by tissue damage often require assembly of inflammasomes, cytoplasmic 
multiprotein complexes incorporating caspase-1, that are required for proteolytic activation of 
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IL-1 (Lamkanfi, 2011). Formation of active inflammasomes is observed in fibroblasts, 
neutrophils, macrophages and endothelial cells within granulation tissue following 
experimental MI, and in cardiomyocytes bordering the infarct zone (Mezzaroma et al., 2011; 
Kawaguchi et al., 2011).  
  
3.2. IL-1 signalling 
The biological effects of IL-1 and IL-1β are mediated through binding to their cognate 
receptor, IL-1R1. Ligand binding stimulates recruitment of the IL-1 receptor accessory 
protein (IL-1RacP) which in turn recruits the MyD88 (myeloid differentiation factor 88) and 
IRAK4 (IL-1 receptor-activated protein kinase 4) signalling proteins (Figure 1). This 
tetrameric complex is formed within seconds of IL-1 binding and acts as a stable first 
signalling module (Brikos et al., 2007; Weber et al., 2010). A complex assortment of 
additional adaptor proteins and kinases (e.g. TRAF6, TOLLIP, IRAK-1, IRAK-2) are then 
recruited to the core IL-1R1 signalling module, facilitating activation of downstream 
signalling pathways including the MAP kinase (ERK, p38, JNK) and NFB cascades (Weber 
et al., 2010). Whilst the vast majority of IL-1R1 signalling has been shown to have an 
absolute requirement for the MyD88 adaptor protein (Adachi et al., 1998), IL-1R1 can 
activate the PI3K/Akt pathway via both MyD88-dependent and -independent mechanisms in 
some cell types (Davis et al., 2006; Ko et al., 2011) (Figure 1). 
 Several negative regulators of the signalling pathways downstream of IL-1R1 have 
also been described (O'Neill, 2008; Flannery and Bowie, 2010). These include the tyrosine 
phosphatases SHP-1 and SHP-2 and the suppressors of cytokine signalling SOCS-1 and 
SOCS-3. IRAK-M is a novel member of the IRAK family that is particularly highly 
expressed in monocytes and macrophages, but has also been shown to be expressed by CF 
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(Chen et al., 2012). IRAK-M lacks kinase activity and acts as a negative regulator of IL-1R1 
signalling.    
 Negative regulation of IL-1 signalling at the receptor level occurs in several ways 
(Dinarello, 2005; Dinarello, 2011). Firstly, IL-1/β can bind to a second cell-surface IL-1 
receptor, IL-1R2, which lacks the cytosolic domain and therefore acts as a decoy receptor that 
is unable to activate intracellular signalling pathways. Secondly, IL-1RA acts as a natural 
receptor antagonist by binding to IL-1R1, but it does not elicit downstream signalling as IL-
1RAcP is not recruited. Finally, IL-1/β can be sequestered in the plasma by soluble forms of 
the IL-1R2 and IL-1RAcP proteins (sIL-1R2 and sIL-1RAcP) that are formed following 
inducible receptor cleavage.  
 
3.3. Role of IL-1R1 signalling in post-MI cardiac remodelling 
IL-1 levels are generally elevated in the first few hours after MI and return to basal levels 
within 3 days, although this varies depending on the species in question (Dewald et al., 
2004). For example, IL-1β mRNA levels in rat myocardium are markedly elevated over a 3-
24 h period following experimental MI (without reperfusion) and return to basal levels within 
3 days (Deten et al., 2002). In a reperfused mouse MI model, IL-1β mRNA was elevated 3-6 
h after MI and returned to basal levels within 3 days (Dewald et al., 2004). In MI patients, 
plasma levels of IL-1β are transiently elevated 1-5 h after infarction before returning to 
control levels (Guillen et al., 1995). 
Both IL-1 and IL-1β are able to drive cardiac dysfunction in animal models. For 
example, transgenic mice with cardiomyocyte-specific overexpression of IL-1 develop LV 
hypertrophy (Nishikawa et al., 2006), while those ubiquitously over-expressing IL-1 die of 
heart failure within 2 weeks of birth (Isoda et al., 2001). Moreover, intraperitoneal injection 
of IL-1β induces proinflammatory cytokine expression, cardiac fibrosis and heart failure in 
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mice within 3 weeks (Blyszczuk et al., 2009; Van Tassell et al., 2010). 
 Knockout mouse studies have revealed a critical role for the IL-1 receptor in 
mediating cardiac myofibroblast accumulation, MMP expression and fibrotic remodelling of 
the infarcted heart (Bujak et al., 2008). The beneficial effects on cardiac remodelling 
observed in IL-1R1 knockout mice were not only the result of suppressed inflammation, but 
also attributed to the loss of direct IL-1-mediated effects on CF (Bujak et al., 2008). MyD88 
and IL-1R1 signalling were also shown to be critical for development of cardiac fibrosis 
during progression to heart failure in a mouse model of inflammatory heart disease; effects 
shown to be mediated predominantly at the level of CF progenitor cells (Blyszczuk et al., 
2009). A recent study demonstrated that IRAK-M, a negative regulator of IL-1R1 signalling, 
was upregulated in both macrophages and fibroblasts infiltrating the infarcted heart (Chen et 
al., 2012). As well as being important for preventing excessive inflammatory activation of 
macrophages, IRAK-M also appeared to restrain fibroblast-derived matrix-degrading activity 
(Chen et al., 2012). 
 The above findings, together with a wealth of other pre-clinical data (reviewed by 
(Bujak and Frangogiannis, 2009; Dinarello et al., 2012; Abbate et al., 2012), suggest that 
inhibition of IL-1 signalling may be an effective therapeutic strategy for improving cardiac 
function and outcome following MI (Abbate et al., 2010b; Van Tassell et al., 2010). 
Subsequent clinical trials have evaluated one such approach in MI patients, namely 
subcutaneous injection of a recombinant form of the human IL-1RA, Anakinra. In these 
randomised studies, patients were injected with a single daily dose of 100 mg Anakinra or 
placebo over a 2-week period. In the VCU-ART small pilot study of 10 patients with acute 
myocardial infarction with ST-segment elevation (STEMI), Anakinra administered within a 
few hours of the onset of symptoms appeared to have beneficial effects on cardiac 
remodelling (Abbate et al., 2010a). However, in the recently reported VCU-ART2 follow-up 
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trial with 30 clinically stable STEMI patients, early Anakinra administration did not show 
significant improvement in cardiac function although it did blunt the acute inflammatory 
response (Abbate et al., 2013). The outcome of the larger MRC-ILA-HEART study in 182 
patients with smaller infarcts (non-STEMI) treated with or without Anakinra (Crossman et 
al., 2008) is expected soon, however this also appears likely to produce disappointing results 
(Morton et al., 2011). Thus, despite encouraging pre-clinical data, these preliminary findings 
in MI patients suggest that blanket inhibition of IL-1 signalling does not offer the anticipated 
beneficial effects on cardiac remodelling.  
 The discrepancy between these early clinical results and the strong preclinical animal 
data obtained with recombinant IL-1RA may relate in part to the larger severity of cardiac 
remodelling induced in experimental MI models compared with the relatively low level of 
LV dysfunction observed in the STEMI (Abbate et al., 2010a; Abbate et al., 2013) or non-
STEMI (Crossman et al., 2008; Morton et al., 2011) patient cohorts studied. Whether more 
pronounced beneficial effects of Anakinra would be observed with a group of patients at 
greater risk of severe cardiac remodelling remains to be determined. It is also a possibility 
that more targeted approaches aimed at IL-1 responses in individual cardiac cell types may 
offer superior outcomes, and pre-clinical studies are needed to evaluate this hypothesis.   
 
4. Effects of Interleukin-1 on Cardiac Fibroblast Function 
Studying the effect of IL-1 on CF function in vivo is complicated because of the interplay 
between different cell types through intercellular autocrine/paracrine signalling. Thus, much 
of our knowledge on the direct effects of IL-1 on CF has come from in vitro cell culture 
studies. Whilst these systems are some way from the physiological situation they are useful in 
that they allow direct transcriptional and functional responses to be measured, as well as the 
underlying molecular mechanisms. Many studies have used neonatal rat CF as a convenient 
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model system, although these cells may exhibit significant differences compared with adult 
cells, and compared with CF derived from other species (Porter and Turner, 2009). In our 
laboratory we have studied adult human CF cultured from different patients to gain a more 
accurate picture of the mechanisms underlying CF function in man.       
 
4.1. Cell proliferation, migration and differentiation 
For several years, the general consensus has been that IL-1 inhibits CF proliferation, although 
most of the evidence for this notion comes from studies using cultured neonatal rat CF 
(Palmer et al., 1995; Koudssi et al., 1998; Piacentini et al., 2000; Xiao et al., 2008). In 
contrast, some recent reports have described increased proliferation of neonatal and adult rat 
CF in response to IL-1 (He et al., 2011; Szardien et al., 2012), although the reasons for these 
opposing results are not immediately apparent. We are not aware of any reports describing 
the effects of IL-1 on human CF proliferation. 
 IL-1 is a chemoattractant for several cell types and has been shown to be a potent 
inducer of in vitro cell migration of both neonatal and adult rat CF (Mitchell et al., 2007; 
Brown et al., 2007), as well as adult human CF (Mughal et al., 2009).  
 IL-1β was shown to reduce myofibroblast differentiation (i.e. the proportion of 
SMA-positive cells) in a recent study on neonatal rat CF (Szardien et al., 2012). Moreover, 
we recently demonstrated that IL-1, even at relatively low concentrations (0.1 ng/ml), could 
oppose the ability of TGFβ to induce fibroblast-to-myofibroblast differentiation (van 
Nieuwenhoven et al., 2013). IL-1 caused a marked reduction in TGFβ-induced SMA 
mRNA and protein expression in human CF and also reduced their ability to contract 
collagen gels, a functional assay for myofibroblast activity (van Nieuwenhoven et al., 2013). 
 
4.2. Inflammatory gene expression in CF  
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In order to create an overview of the many effects of IL-1 on CF function we have 
undertaken several studies in recent years to investigate IL-1-induced changes in gene 
expression in human CF. Cells were cultured from atrial tissue biopsies from multiple 
patients undergoing coronary artery bypass surgery and were found to consistently co-express 
vimentin and SMA throughout culture over several passages (Mughal et al., 2009), 
characteristic of the myofibroblast phenotype. We studied the effects of IL-1 on expression 
of proinflammatory cytokines, chemokines, adhesion molecules, angiogenic factors and 
molecules involved in ECM synthesis and degradation (Figure 2). IL-1 was found to be a 
potent stimulator of several proinflammatory cytokines including IL-1, IL-1β, TNF, IL-6 
and leukaemia inhibitory factor (LIF), but not the other IL-6 family members cardiotrophin-1 
or oncostatin M (Turner et al., 2009). IL-1 also stimulated gene expression and secretion of 
the neutrophil-attracting CXC chemokines CXCL-1 (KC/GRO), CXCL-2 (MIP-2a/GROβ), 
CXCL-5 (ENA-78) and CXCL-8 (IL-8) (Turner et al., 2011). Using a focused RT-PCR 
microarray we identified a number of inflammatory adhesion molecules that were also 
upregulated following IL-1 stimulation, including ICAM-1, VCAM-1, E-selectin and to a 
lesser extent the integrin β3 subunit and CD44 (Turner et al., 2011). Another important 
myocardial proinflammatory cytokine, TNF, was able to stimulate a similar profile of 
cytokines, chemokines and adhesion molecules in human CF; however it was consistently 
less potent than IL-1 (Turner et al., 2007; Turner et al., 2009; Turner et al., 2011). This 
relative sensitivity of CF to IL-1 is in agreement with previous reports that fibroblasts in the 
heart are particularly responsive to IL-1 compared with other cytokines, and compared with 
other sources of fibroblasts (Brown et al., 2005). 
 
4.3. Synthesis and degradation of ECM by CF 
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We used a focused RT-PCR microarray to evaluate mRNA levels of structural ECM proteins, 
MMPs and TIMPs in cultured human CF and their modulation by IL-1 (Turner et al., 2010). 
Human CF expressed relatively high basal levels of multiple ECM proteins under basal levels 
including collagens I, IV, V, VI, VIII, XII and XIV, laminins 2, β1 and 1 and fibronectin, 
but none of these were markedly affected by IL-1 stimulation over a 6 h period (Turner et al., 
2010). It is possible that IL-1 may modulate expression of some ECM proteins at later time 
points, particularly as we have since observed a 20% reduction in COL1A1 mRNA 
expression 24 h after stimulation with 10 ng/ml IL-1; an inhibition that was not evident after 
6 h (N.A. Turner, unpublished observation). This finding is in agreement with earlier studies 
in neonatal and adult rat CF (Siwik et al., 2000; Xiao et al., 2008), and appears to be specific 
for fibrillar collagens. Interestingly, we also reported recently that IL-1 can rapidly (within 
4 h) and potently (by up to 80%) reduce protein levels of the profibrotic matricellular protein 
CTGF/CCN2 in human CF (Maqbool et al., 2013). It is therefore possible that the delayed 
inhibitory effect of IL-1 on COL1A1 gene expression occurs indirectly via an 
autocrine/paracrine feedback loop involving down-regulation of profibrotic factors such as 
CTGF/CCN2.  
 CF are capable of expressing several, but not all, members of the MMP family in a 
regulated manner (Turner and Porter, 2012). In our own studies, human CF were found to 
express particularly high basal mRNA levels of MMP-1 (interstitial collagenase), MMP-2 
(gelatinase A), MMP-14 (MT1-MMP) and MMP-16 (MT3-MMP), and even higher levels of 
TIMP-1 and TIMP-2, but not TIMP-3 (Turner et al., 2010). Exposure of cells to IL-1 (10 
ng/ml, 6 h) elicited 80-200-fold increases in mRNA levels of MMP-3 (stromelysin 1), MMP-
9 (gelatinase B) and MMP-10 (stromelysin 2), and an 8-fold increase in MMP-1, while 
TIMP-2 mRNA levels were increased by a modest 2-fold (Turner et al., 2010). IL-1 was also 
previously reported to stimulate MMP-3 and MMP-9 expression in neonatal and adult rat CF 
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(Siwik et al., 2000; Brown et al., 2007). Studies using human and rat CF have reported 
additional stimulatory effects of IL-1 on MMP-2 expression and activity (Siwik et al., 2000; 
Brown et al., 2007; Guo et al., 2008), although we did not observe this in our own shorter-
term studies (Turner et al., 2010).     
 Protein and mRNA expression levels of ADAMTS1, a protease that is a potent 
inhibitor of angiogenesis, were rapidly reduced following IL-1 treatment (Turner et al., 
2010), and this finding coupled with the up-regulation of VEGF mRNA by IL-1 (Turner et 
al., 2010) would suggest a pro-angiogenic effect of IL-1 at the level of the fibroblast.  
 Taking all these data together, we propose that by modulating expression of a specific 
subset of genes, IL-1 can stimulate human CF to adopt a pro-inflammatory, pro-angiogenic, 
pro-migratory, ECM degrading phenotype, whilst suppressing myofibroblast differentiation 
(Figure 2). These findings are of particular relevance to the early inflammatory phase of 
post-MI infarct healing when IL-1 levels are elevated, prior to myofibroblast activation, ECM 
synthesis and scar maturation (van Nieuwenhoven and Turner, 2013; Chen and 
Frangogiannis, 2012).  
 
4.4. IL-1 signalling in CF 
IL-1/β stimulates all the major canonical kinase signalling cascades in CF (Figure 1), 
including the ERK, JNK, p38, PI3K/Akt and NFB pathways (Xie et al., 2004; Mitchell et 
al., 2007; Turner et al., 2009). All of these pathways have also been shown to be activated in 
the myocardium early after experimental MI; see recent comprehensive reviews on NF-κB 
(Gordon et al., 2011), p38 (Marber et al., 2011; Turner, 2011), JNK (Turner, 2011), ERK and 
Akt; the latter being components of the reperfusion injury salvage kinase (RISK) pathway 
that is considered cardioprotective (Hausenloy et al., 2005). However, these studies do not 
shed particular light on IL-1 signalling in CF due to the heterogeneity of cell types in the 
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heart and the multitude of potential stimuli for these pathways after MI (in addition to IL-1). 
Only a very few in vivo studies have attempted to study signalling pathways at a cellular level 
post-MI. One particularly good example of this is a recent study by Yeh and colleagues that 
used a permanent LAD occlusion model to reveal differential temporal changes in ERK and 
p38 (and to a lesser extent JNK and Akt) activation in distinct cell types in infarcted and 
remote areas of the mouse myocardium over a 1-12 week period (Yeh et al., 2010). Clearly 
the specific role of IL-1-induced signalling pathways in CF in vivo is extremely difficult to 
evaluate and hence most of our current understanding has been obtained from in vitro CF 
cultures treated with IL-1.  
We used pharmacological inhibitors to delineate the pathways responsible for 
mediating increases in gene expression in cultured human CF (Turner et al., 2009; Turner et 
al., 2010; Turner et al., 2011). These studies (summarised in Table 1) revealed major roles 
for the NFB and p38 MAPK pathways in mediating IL-1-induced expression of multiple 
proinflammatory genes. NFB-regulated genes included IL-1β, TNF, IL-8, ICAM-1 and E-
selectin. Although we did not evaluate the role of NFB signalling in mediating expression of 
MMPs in human CF, previous studies suggest that several of the major MMPs expressed by 
CF (including MMPs 1, 3 and 9) are regulated via this pathway due to NFB binding sites in 
their gene promoter regions (Turner and Porter, 2012).  
 The p38 MAPK pathway plays an important role in regulating various aspects of the 
myocardial remodelling process, including CF function (Marber et al., 2011; Turner, 2011). 
The IL-1-induced, p38-regulated genes that we identified using the p38-/β-selective 
inhibitor SB203580 included IL-6, IL-8, TNF and MMP-3 (Table 1). We therefore 
investigated the role of individual p38 MAPK subtypes in mediating IL-1-induced IL-6 and 
MMP-3 gene expression in human CF (Sinfield et al., 2013). Quantitative RT-PCR and 
Western blotting of cells from multiple patients revealed a consistent pattern of p38 subtype 
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expression in human CF, with p38- being most abundant, followed by p38- and p38-, and 
little or no expression of p38-β (Sinfield et al., 2013). This pattern of subtype expression is 
similar to that of whole heart tissue from adult humans (Lemke et al., 2001). Treatment of 
human CF with IL-1 led to selective activation of p38- and p38- (Sinfield et al., 2013). 
Moreover, the p38-/β-selective inhibitor SB203580 ablated IL-1-induced IL-6 and MMP-3 
gene expression (Turner et al., 2009; Turner et al., 2010). We subsequently confirmed a 
specific role for p38- in mediating the effects of IL-1 on IL-6 and MMP-3 expression and 
secretion in these cells by using an siRNA gene silencing strategy to selectively knock down 
the p38- subtype (Sinfield et al., 2013). 
  
4.5. Important considerations 
In the course of these studies we have noted some potentially important differences in the 
signalling pathways regulating expression of specific genes in human CF compared with CF 
from other species. For example in our studies using human CF, IL-1-induced MMP-3 
expression was found to be p38-dependent whereas IL-1-induced MMP-9 expression was 
p38-independent (Turner et al., 2010; Sinfield et al., 2013). However, the exact opposite was 
previously reported in adult rat CF in which IL-1-induced MMP-3 expression was p38-
independent and IL-1-induced MMP-9 expression was p38-dependent (Brown et al., 2007). 
Whether such discrepancies relate to genuine differences in regulatory mechanisms between 
different species is an important issue that requires clarification as this could be an important 
consideration when modelling human disease. 
It is worth noting that our studies on human CF used atrial fibroblasts from multiple 
patients with coronary artery disease. It is feasible that CF from different regions of the heart 
may exhibit differences in their functional responses, as has been reported for canine cells 
(Burstein et al., 2008). It is also possible that CF derived from our cohort of donors may have 
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modified function compared with those from “healthy” subjects, although we have no 
evidence to support this notion.  
 Another consideration that should be highlighted is that under physiological 
conditions, CF are exposed to a plethora of bioactive molecules and the net effect on cell 
function depends on relative amounts of these stimulatory and inhibitory signals that vary in a 
spatiotemporal manner. Therefore whilst we can gain mechanistic insights from studying 
responses to a single stimulus such as IL-1 in isolation, we should keep in mind that this is a 
vast over-simplification of the in vivo scenario. Indeed, we have recently reported that even 
when studying just two cytokines (IL-1 and TGFβ), a complex interplay between factors 
becomes evident at the level of gene expression and human CF function (van Nieuwenhoven 
et al., 2013).  
 
5. Conclusions 
Fibroblasts play a critical role in many aspects of post-MI remodelling and as such represent 
a viable therapeutic target for reducing adverse cardiac remodelling and its devastating 
consequences. Understanding the origin, role and regulation of CF in the remodelling heart is 
therefore imperative to guide such strategies. IL-1 is a proinflammatory cytokine that is an 
early trigger of post-MI remodelling and has multiple effects on CF function. Emerging 
clinical studies suggest that blanket inhibition of IL-1 signalling does not offer beneficial 
effects on post-MI remodelling in man. However, more targeted approaches aimed at the IL-
1/CF axis may offer superior outcomes, and pre-clinical studies are needed to evaluate this 
hypothesis.   
 
 
     
19 
 
References 
 
Abbate, A., Kontos, M.C., Grizzard, J.D., Biondi-Zoccai, G.G., Van Tassell, B.W., Robati, 
R., Roach, L.M., Arena, R.A., Roberts, C.S., Varma, A., Gelwix, C.C., Salloum, F.N., 
Hastillo, A., Dinarello, C.A., Vetrovec, G.W., 2010a. Interleukin-1 blockade with anakinra 
to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia 
Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. 
Cardiol. 105, 1371-1377. 
Abbate, A., Van Tassell, B.W., Biondi-Zoccai, G., Kontos, M.C., Grizzard, J.D., Spillman, 
D.W., Oddi, C., Roberts, C.S., Melchior, R.D., Mueller, G.H., Abouzaki, N.A., Rengel, 
L.R., Varma, A., Gambill, M.L., Falcao, R.A., Voelkel, N.F., Dinarello, C.A., Vetrovec, 
G.W., 2013. Effects of interleukin-1 blockade with Anakinra on adverse cardiac 
remodeling and heart failure after acute myocardial infarction [from the Virginia 
Commonwealth University-Anakinra Remodeling Trial 2 (VCU-ART2) Pilot Study]. Am. 
J. Cardiol. 
Abbate, A., Van Tassell, B.W., Biondi-Zoccai, G.G., 2012. Blocking interleukin-1 as a novel 
therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs. 26, 217-
233. 
Abbate, A., Van Tassell, B.W., Seropian, I.M., Toldo, S., Robati, R., Varma, A., Salloum, 
F.N., Smithson, L., Dinarello, C.A., 2010b. Interleukin-1beta modulation using a 
genetically engineered antibody prevents adverse cardiac remodelling following acute 
myocardial infarction in the mouse. Eur. J. Heart Fail. 12, 319-322. 
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, 
K., Akira, S., 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-
18-mediated function. Immunity. 9, 143-150. 
20 
 
Arend, W.P., Palmer, G., Gabay, C., 2008. IL-1, IL-18, and IL-33 families of cytokines. 
Immunol. Rev. 223, 20-38. 
Arslan, F., de Kleijn, D.P., Pasterkamp, G., 2011. Innate immune signaling in cardiac 
ischemia. Nat. Rev. Cardiol. 8, 292-300. 
Banerjee, I., Fuseler, J.W., Price, R.L., Borg, T.K., Baudino, T.A., 2007. Determination of 
cell types and numbers during cardiac development in the neonatal and adult rat and 
mouse. Am. J. Physiol Heart Circ. Physiol 293, H1883-H1891. 
Blyszczuk, P., Kania, G., Dieterle, T., Marty, R.R., Valaperti, A., Berthonneche, C., 
Pedrazzini, T., Berger, C.T., Dirnhofer, S., Matter, C.M., Penninger, J.M., Luscher, T.F., 
Eriksson, U., 2009. Myeloid differentiation factor-88/interleukin-1 signaling controls 
cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. 
Circ. Res. 105, 912-920. 
Brikos, C., Wait, R., Begum, S., O'Neill, L.A., Saklatvala, J., 2007. Mass spectrometric 
analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed 
after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. 
Mol. Cell Proteomics. 6, 1551-1559. 
Brown, R.D., Ambler, S.K., Mitchell, M.D., Long, C.S., 2005. The cardiac fibroblast: 
therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 
45, 657-687. 
Brown, R.D., Jones, G.M., Laird, R.E., Hudson, P., Long, C.S., 2007. Cytokines regulate 
matrix metalloproteinases and migration in cardiac fibroblasts. Biochem. Biophys. Res. 
Commun. 362, 200-205. 
Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L.H., Li, N., Reddy, A., Frangogiannis, 
N.G., 2008. Interleukin-1 receptor type I signaling critically regulates infarct healing and 
cardiac remodeling. Am. J. Pathol. 173, 57-67. 
21 
 
Bujak, M., Frangogiannis, N.G., 2009. The role of IL-1 in the pathogenesis of heart disease. 
Arch. Immunol. Ther. Exp. (Warsz. ) 57, 165-176. 
Burstein, B., Libby, E., Calderone, A., Nattel, S., 2008. Differential behaviors of atrial versus 
ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-
ventricular remodeling differences. Circulation 117, 1630-1641. 
Camelliti, P., Green, C.R., Kohl, P., 2006. Structural and functional coupling of cardiac 
myocytes and fibroblasts. Adv. Cardiol. 42, 132-149. 
Chen, C.J., Kono, H., Golenbock, D., Reed, G., Akira, S., Rock, K.L., 2007. Identification of 
a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. 
Med. 13, 851-856. 
Chen, W., Frangogiannis, N.G., 2012. Fibroblasts in post-infarction inflammation and cardiac 
repair. Biochim. Biophys. Acta. 
Chen, W., Saxena, A., Li, N., Sun, J., Gupta, A., Lee, D.W., Tian, Q., Dobaczewski, M., 
Frangogiannis, N.G., 2012. Endogenous IRAK-M attenuates postinfarction remodeling 
through effects on macrophages and fibroblasts. Arterioscler. Thromb. Vasc. Biol. 32, 
2598-2608. 
Crossman, D.C., Morton, A.C., Gunn, J.P., Greenwood, J.P., Hall, A.S., Fox, K.A., Lucking, 
A.J., Flather, M.D., Lees, B., Foley, C.E., 2008. Investigation of the effect of Interleukin-1 
receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute 
coronary syndromes (The MRC-ILA-HEART Study). Trials 9, 8. 
Davis, C.N., Mann, E., Behrens, M.M., Gaidarova, S., Rebek, M., Rebek, J., Jr., Bartfai, T., 
2006. MyD88-dependent and -independent signaling by IL-1 in neurons probed by 
bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc. Natl. Acad. Sci. U. S. A 
103, 2953-2958. 
22 
 
Demyanets, S., Kaun, C., Pentz, R., Krychtiuk, K.A., Rauscher, S., Pfaffenberger, S., 
Zuckermann, A., Aliabadi, A., Groger, M., Maurer, G., Huber, K., Wojta, J., 2013. 
Components of the interleukin-33/ST2 system are differentially expressed and regulated in 
human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cell Cardiol. In press. 
Deten, A., Volz, H.C., Briest, W., Zimmer, H.G., 2002. Cardiac cytokine expression is 
upregulated in the acute phase after myocardial infarction. Experimental studies in rats. 
Cardiovasc. Res. 55, 329-340. 
Dewald, O., Ren, G., Duerr, G.D., Zoerlein, M., Klemm, C., Gersch, C., Tincey, S., Michael, 
L.H., Entman, M.L., Frangogiannis, N.G., 2004. Of mice and dogs: species-specific 
differences in the inflammatory response following myocardial infarction. Am. J. Pathol. 
164, 665-677. 
Dinarello, C.A., 2005. The many worlds of reducing interleukin-1. Arthritis Rheum. 52, 
1960-1967. 
Dinarello, C.A., 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory 
diseases. Blood 117, 3720-3732. 
Dinarello, C.A., Simon, A., van der Meer, J.W., 2012. Treating inflammation by blocking 
interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652. 
Fernandez-Velasco, M., Prieto, P., Terron, V., Benito, G., Flores, J.M., Delgado, C., 
Zaragoza, C., Lavin, B., Gomez-Parrizas, M., Lopez-Collazo, E., Martin-Sanz, P., Bosca, 
L., 2012. NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and 
cardiomyocyte apoptosis. PLoS. One. 7, e45260. 
Flannery, S., Bowie, A.G., 2010. The interleukin-1 receptor-associated kinases: critical 
regulators of innate immune signalling. Biochem. Pharmacol. 80, 1981-1991. 
Frangogiannis, N.G., 2008. The immune system and cardiac repair. Pharmacol. Res. 58, 88-
111. 
23 
 
Gordon, J.W., Shaw, J.A., Kirshenbaum, L.A., 2011. Multiple facets of NF-B in the heart: 
to be or not to NF-B. Circ. Res. 108, 1122-1132. 
Guillen, I., Blanes, M., Gomez-Lechon, M.J., Castell, J.V., 1995. Cytokine signaling during 
myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am. J. Physiol 269, 
R229-R235. 
Guo, X.G., Uzui, H., Mizuguchi, T., Ueda, T., Chen, J.Z., Lee, J.D., 2008. Imidaprilat 
inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by 
interleukin-1 via NO-dependent pathway. Int. J. Cardiol. 126, 414-420. 
Hausenloy, D.J., Tsang, A., Yellon, D.M., 2005. The reperfusion injury salvage kinase 
pathway: a common target for both ischemic preconditioning and postconditioning. Trends 
Cardiovasc. Med. 15, 69-75. 
He, Y.H., Zhang, H.N., Zhang, G.P., Hou, N., Xiao, Q., Huang, Y., Wu, J.H., Luo, M.S., 
Zhang, G.S., Yi, Q., Chen, M.S., Luo, J.D., 2011. A physiological concentration of 
glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat 
cardiac fibroblasts: roles of extracellular signal-regulated kinase 1/2 and nuclear factor-
kappaB. Clin. Exp. Pharmacol. Physiol 38, 739-746. 
Isoda, K., Kamezawa, Y., Tada, N., Sato, M., Ohsuzu, F., 2001. Myocardial hypertrophy in 
transgenic mice overexpressing human interleukin 1. J. Card Fail. 7, 355-364. 
Jugdutt, B.I., 2003. Ventricular remodeling after infarction and the extracellular collagen 
matrix: when is enough enough? Circulation. 108, 1395-1403. 
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., Izawa, A., 
Takahashi, Y., Masumoto, J., Koyama, J., Hongo, M., Noda, T., Nakayama, J., Sagara, J., 
Taniguchi, S., Ikeda, U., 2011. Inflammasome activation of cardiac fibroblasts is essential 
for myocardial ischemia/reperfusion injury. Circulation 123, 594-604. 
24 
 
Ko, N.Y., Mun, S.H., Lee, S.H., Kim, J.W., Kim, d.K., Kim, H.S., Her, E., Kim, S.H., Won, 
H.S., Shin, H.S., Kim, H.S., Kim, Y.M., Choi, W.S., 2011. Interleukin-32 production is 
regulated by MyD88-dependent and independent pathways in IL-1-stimulated human 
alveolar epithelial cells. Immunobiology 216, 32-40. 
Koudssi, F., Lopez, J.E., Villegas, S., Long, C.S., 1998. Cardiac fibroblasts arrest at the G1/S 
restriction point in response to interleukin (IL)-1. Evidence for IL-1-induced 
hypophosphorylation of the retinoblastoma protein. J. Biol. Chem. 273, 25796-25803. 
Krenning, G., Zeisberg, E.M., Kalluri, R., 2010. The origin of fibroblasts and mechanism of 
cardiac fibrosis. J. Cell Physiol 225, 631-637. 
LaFramboise, W.A., Scalise, D., Stoodley, P., Graner, S.R., Guthrie, R.D., Magovern, J.A., 
Becich, M.J., 2007. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am. 
J. Physiol Cell Physiol 292, C1799-C1808. 
Lamkanfi, M., 2011. Emerging inflammasome effector mechanisms. Nat. Rev. Immunol. 11, 
213-220. 
Lemke, L.E., Bloem, L.J., Fouts, R., Esterman, M., Sandusky, G., Vlahos, C.J., 2001. 
Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK  is 
the predominant isoform expressed in human heart. J. Mol. Cell Cardiol. 33, 1527-1540. 
Long, C.S., 2001. The role of interleukin-1 in the failing heart. Heart Fail. Rev. 6, 81-94. 
Maqbool, A., Hemmings, K.E., O'Regan, D.J., Ball, S.G., Porter, K.E., Turner, N.A., 2013. 
Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C 
expression in human cardiac fibroblasts. Matrix Biol. 32, 208-214. 
Marber, M.S., Rose, B., Wang, Y., 2011. The p38 mitogen-activated protein kinase pathway-
A potential target for intervention in infarction, hypertrophy, and heart failure. J. Mol. Cell 
Cardiol. 51, 485-490. 
25 
 
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I.M., Van Tassell, B.W., Salloum, F.N., 
Kannan, H.R., Menna, A.C., Voelkel, N.F., Abbate, A., 2011. The inflammasome 
promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. 
Proc. Natl. Acad. Sci. U. S. A 108, 19725-19730. 
Mitchell, M.D., Laird, R.E., Brown, R.D., Long, C.S., 2007. IL-1 stimulates rat cardiac 
fibroblast migration via MAP kinase pathways. Am. J. Physiol Heart Circ. Physiol 292, 
H1139-H1147. 
Morton, A.C., Foley, C., Rothman, A., Gunn, J., Greenwood, J.P., Hall, A., Fox, K., Lees, B., 
Flather, M., Crossman, D., 2011. Investigation of IL-1 inhibition in patients presenting 
with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA 
Heart Study). Heart 97, A13 (abstract) doi:10.1136/heartjnl-2011-300198.15. 
Mughal, R.S., Warburton, P., O'Regan, D.J., Ball, S.G., Turner, N.A., Porter, K.E., 2009. 
Peroxisome proliferator-activated receptor -independent effects of thiazolidinediones on 
human cardiac myofibroblast function. Clin. Exp. Pharmacol. Physiol. 36, 478-486. 
Nishikawa, K., Yoshida, M., Kusuhara, M., Ishigami, N., Isoda, K., Miyazaki, K., Ohsuzu, 
F., 2006. Left ventricular hypertrophy in mice with a cardiac-specific overexpression of 
interleukin-1. Am. J. Physiol Heart Circ. Physiol 291, H176-H183. 
O'Neill, L.A., 2008. When signaling pathways collide: positive and negative regulation of 
toll-like receptor signal transduction. Immunity. 29, 12-20. 
Palmer, J.N., Hartogensis, W.E., Patten, M., Fortuin, F.D., Long, C.S., 1995. Interleukin-1 
induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J. 
Clin. Invest 95, 2555-2564. 
Peterson, D.J., Ju, H., Hao, J., Panagia, M., Chapman, D.C., Dixon, I.M., 1999. Expression of 
Gi-2 alpha and Gs alpha in myofibroblasts localized to the infarct scar in heart failure due 
to myocardial infarction. Cardiovasc. Res. 41, 575-585. 
26 
 
Piacentini, L., Gray, M., Honbo, N.Y., Chentoufi, J., Bergman, M., Karliner, J.S., 2000. 
Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein 
kinase C. J. Mol. Cell Cardiol. 32, 565-576. 
Porter, K.E., Turner, N.A., 2009. Cardiac fibroblasts: at the heart of myocardial remodeling. 
Pharmacol. Ther. 123, 255-278. 
Sinfield, J.K., Das, A., O'Regan, D.J., Ball, S.G., Porter, K.E., Turner, N.A., 2013. p38 
MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac 
fibroblasts. Biochem. Biophys. Res. Commun. 430, 419-424. 
Siwik, D.A., Chang, D.L., Colucci, W.S., 2000. Interleukin-1 and tumor necrosis factor- 
decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac 
fibroblasts in vitro. Circ. Res. 86, 1259-1265. 
Strand, M.E., Herum, K.M., Rana, Z.A., Skrbic, B., Askevold, E.T., Dahl, C.P., Vistnes, M., 
Hasic, A., Kvaloy, H., Sjaastad, I., Carlson, C.R., Tonnessen, T., Gullestad, L., 
Christensen, G., Lunde, I.G., 2013. Innate immune signaling induces expression and 
shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and 
myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J. 
Szardien, S., Nef, H.M., Voss, S., Troidl, C., Liebetrau, C., Hoffmann, J., Rauch, M., Mayer, 
K., Kimmich, K., Rolf, A., Rixe, J., Troidl, K., Kojonazarov, B., Schermuly, R.T., Kostin, 
S., Elsasser, A., Hamm, C.W., Mollmann, H., 2012. Regression of cardiac hypertrophy by 
granulocyte colony-stimulating factor-stimulated interleukin-1 synthesis. Eur. Heart J. 
33, 595-605. 
Timmers, L., Sluijter, J.P., van Keulen, J.K., Hoefer, I.E., Nederhoff, M.G., Goumans, M.J., 
Doevendans, P.A., van Echteld, C.J., Joles, J.A., Quax, P.H., Piek, J.J., Pasterkamp, G., de 
Kleijn, D.P., 2008. Toll-like receptor 4 mediates maladaptive left ventricular remodeling 
and impairs cardiac function after myocardial infarction. Circ. Res. 102, 257-264. 
27 
 
Tomasek, J.J., Gabbiani, G., Hinz, B., Chaponnier, C., Brown, R.A., 2002. Myofibroblasts 
and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 
349-363. 
Turner, N.A., 2011. Therapeutic regulation of cardiac fibroblast function: targeting stress-
activated protein kinase pathways. Fut. Cardiol. 7, 673-691. 
Turner, N.A., Das, A., O'Regan, D.J., Ball, S.G., Porter, K.E., 2011. Human cardiac 
fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to 
proinflammatory cytokine stimulation. Int. J. Biochem. Cell Biol. 43, 1450-1458. 
Turner, N.A., Das, A., Warburton, P., O'Regan, D.J., Ball, S.G., Porter, K.E., 2009. 
Interleukin-1 stimulates pro-inflammatory cytokine expression in human cardiac 
myofibroblasts. Am. J. Physiol Heart Circ. Physiol 297, H1117-H1127. 
Turner, N.A., Mughal, R.S., Warburton, P., O'Regan, D.J., Ball, S.G., Porter, K.E., 2007. 
Mechanism of TNF-induced IL-1, IL-1 and IL-6 expression in human cardiac 
fibroblasts: Effects of statins and thiazolidinediones. Cardiovasc. Res. 76, 81-90. 
Turner, N.A., Porter, K.E., 2012. Regulation of myocardial matrix metalloproteinase 
expression and activity by cardiac fibroblasts. IUBMB. Life 64, 143-150. 
Turner, N.A., Porter, K.E., 2013. Function and fate of myofibroblasts after myocardial 
infarction. Fibrogenesis. Tissue Repair 6, 5. 
Turner, N.A., Warburton, P., O'Regan, D.J., Ball, S.G., Porter, K.E., 2010. Modulatory effect 
of interleukin-1 on expression of structural matrix proteins, MMPs and TIMPs in human 
cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol. 29, 613-620. 
van den Borne, S.W., Diez, J., Blankesteijn, W.M., Verjans, J., Hofstra, L., Narula, J., 2010. 
Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 
30-37. 
28 
 
van Nieuwenhoven, F.A., Hemmings, K.E., Porter, K.E., Turner, N.A., 2013. Combined 
effects of interleukin-1 and transforming growth factor-1 on modulation of human 
cardiac fibroblast function. Matrix Biol. In press doi: 10.1016/j.matbio.2013.03.008. 
van Nieuwenhoven, F.A., Turner, N.A., 2013. The role of cardiac fibroblasts in the transition 
from inflammation to fibrosis following myocardial infarction. Vascul. Pharmacol. 58, 
182-188. 
Van Tassell, B.W., Varma, A., Salloum, F.N., Das, A., Seropian, I.M., Toldo, S., Smithson, 
L., Hoke, N.N., Chau, V.Q., Robati, R., Abbate, A., 2010. Interleukin-1 trap attenuates 
cardiac remodeling after experimental acute myocardial infarction in mice. J. Cardiovasc. 
Pharmacol. 55, 117-122. 
Weber, A., Wasiliew, P., Kracht, M., 2010. Interleukin-1 (IL-1) pathway. Sci. Signal. 3, cm1. 
Werman, A., Werman-Venkert, R., White, R., Lee, J.K., Werman, B., Krelin, Y., Voronov, 
E., Dinarello, C.A., Apte, R.N., 2004. The precursor form of IL-1 is an intracrine 
proinflammatory activator of transcription. Proc. Natl. Acad. Sci. U. S. A 101, 2434-2439. 
Westphal, E., Li, C., Pilowski, C., Koch, S., Ebelt, H., Muller-Werdan, U., Werdan, K., 
Loppnow, H., 2007. Endotoxin-activated cultured neonatal rat cardiomyocytes express 
functional surface-associated interleukin-1. J. Endotoxin. Res. 13, 25-34. 
Willems, I.E., Havenith, M.G., De Mey, J.G., Daemen, M.J., 1994. The alpha-smooth muscle 
actin-positive cells in healing human myocardial scars. Am. J. Pathol. 145, 868-875. 
Xiao, H., Ji, A.M., Li, Z.L., Song, X.D., Su, D., Chen, A.H., 2008. Interleukin-1 inhibits 
collagen synthesis and promotes its decomposition in cultured cardiac fibroblasts. Sheng 
Li Xue. Bao. 60, 355-361. 
Xie, Z., Singh, M., Singh, K., 2004. Differential regulation of matrix metalloproteinase-2 and 
-9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1. J. 
Biol. Chem. 279, 39513-39519. 
29 
 
Yeh, C.C., Li, H., Malhotra, D., Turcato, S., Nicholas, S., Tu, R., Zhu, B.Q., Cha, J., Swigart, 
P.M., Myagmar, B.E., Baker, A.J., Simpson, P.C., Mann, M.J., 2010. Distinctive ERK and 
p38 signaling in remote and infarcted myocardium during post-MI remodeling in the 
mouse. J. Cell Biochem. 109, 1185-1191. 
Zeisberg, E.M., Kalluri, R., 2010. Origins of cardiac fibroblasts. Circ. Res. 107, 1304-1312. 
Zhang, X., Azhar, G., Nagano, K., Wei, J.Y., 2001. Differential vulnerability to oxidative 
stress in rat cardiac myocytes versus fibroblasts. J. Am. Coll. Cardiol. 38, 2055-2062. 
Zhao, L., Eghbali-Webb, M., 2001. Release of pro- and anti-angiogenic factors by human 
cardiac fibroblasts: effects on DNA synthesis and protection under hypoxia in human 
endothelial cells. Biochim. Biophys. Acta 1538, 273-282. 
Zheng, Y., Gardner, S.E., Clarke, M.C., 2011. Cell death, damage-associated molecular 
patterns, and sterile inflammation in cardiovascular disease. Arterioscler. Thromb. Vasc. 
Biol. 31, 2781-2786. 
 
 
30 
 
Figure Legends 
Figure 1. IL-1 receptor signalling. IL-1 or IL-β binding to the IL-1 receptor (IL-1R1) 
stimulates recruitment of the IL-1 receptor accessory protein (IL-1RAcP). This in turn 
facilitates association with MyD88 (myeloid differentiation factor 88) and IRAK4 (IL-1 
receptor-activated protein kinase 4) signalling proteins. Activation of MAP kinase (ERK, 
p38, JNK), NFB and PI-3-kinase/Akt pathways occur in a MyD88-dependent manner after 
recruitment of additional adaptor proteins and kinases. Activation of the Akt pathway can 
also be MyD88-independent in some cell types.  
 
Figure 2. Effects of IL-1 on human cardiac fibroblast function. IL-1 modulates expression 
of specific genes in human CF to promote a pro-inflammatory, pro-angiogenic, pro-
migratory, ECM degrading, non-differentiated fibroblast phenotype. Figure summarises 
results previously published by our group using human CF from multiple patients (Mughal et 
al., 2009; Turner et al., 2009; Turner et al., 2010; Turner et al., 2011; Maqbool et al., 2013; 
van Nieuwenhoven et al., 2013). See main text for details.   
 
Table legends 
Table 1. Role of specific signalling pathways in mediating the effects of IL-1 on human 
CF gene and protein expression. Pharmacological inhibitors were used to delineate the 
signalling pathways underlying IL-1-induced increases in gene and protein expression in 
human CF. Specific inhibitors were PD98059 (ERK pathway inhibitor), SB203580 (p38 
MAPK pathway inhibitor), SP600125 (JNK pathway inhibitor), LY294002 (PI-3-kinase/Akt 
pathway inhibitor) and IMD-0354 (NFB pathway inhibitor). “+” and “-”symbols represent 
positive and negative roles of the pathways respectively, with a greater number of symbols 
indicating a larger influence. Empty grey boxes represent lack of effect of inhibitor, while 
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cross-hatch boxes indicate pathway not studied. Summary is based on previously published 
RT-PCR, Western blotting and ELISA data from our laboratory (Turner et al., 2009; Turner 
et al., 2011; Turner et al., 2010). 
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Table 1
Gene mRNA/protein ERK p38 JNK PI3K NFB Reference 
IL-1β mRNA    + ++ 
Turner et al., 2009 IL-6 mRNA - ++ -   
TNF mRNA  ++   ++ 
IL-8 mRNA      
Turner et al., 2011 
prot  ++   +++ 
ICAM-1 mRNA     ++ 
prot     +++ 
E-Selectin mRNA -  - -  + 
prot   - -  +++ 
MMP-1  mRNA      
Turner et al., 2010 
MMP-2  mRNA      
MMP-3 mRNA  +++    
MMP-9 mRNA      
MMP-10 mRNA      
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Figure 2
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